{
    "nctId": "NCT03719833",
    "briefTitle": "Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents",
    "officialTitle": "Sentinel Lymph Node Biopsy After Neoadjuvant Oncological Treatment in Luminal B, HER-2 Positive and Triple Negative Breast Cancer Patients in Stage T1-3 N0-2 M0 at the Time of Diagnose",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Sentinel Lymph Node Biopsy, Neoadjuvant Chemotherapy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 230,
    "primaryOutcomeMeasure": "Impact of sentinel lymph node biopsy procedure on locoregional recurrence for group 3 sentinel node negative patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must be female\n* Patients must be older than 18 years of age and younger than 80 years of age\n* Patients must have biopsy-proven breast cancer, histological type-ductal, immunophenotype-Luminal B, HER-2 positive and triple-negative\n* Patients with nodal disease (N1-N2) must have fine needle aspiration proven positive node and marked node with titanium clip before onset of neoadjuvant treatment\n* Patients treated (oncological and surgical) in Clinical Hospital Centar Rijeka from September 2018 till May 2022\n* Patients must be in stage cT1-3 cN0-2 cM0 at the time of diagnosis and cN0 at the time of the surgery\n* Patients that are eligible for neoadjuvant oncological treatment, accepting to undergo it and complete it\n* Patients who understand, accept and have signed the approved consent form\n\nExclusion Criteria:\n\n* Patents in T4 stage and/or N3 stage and/or M1 stage at the time of diagnosis\n* Patients with inflammatory carcinoma\n* Patients with bilateral disease\n* Patients with ipsilateral recurrence\n* Patients with histological type-lobular and immunophenotype-Luminal A\n* Patients that are not eligible for oncological treatment according to protocol, either neoadjuvant or adjuvant, or oncological treatment was interrupted (aborted or completed in another institution)\n* Patients that have had previously SLNB or ALND or radiotherapy to the axillary nodes\n* Patients that have been or are treated for other malignant disease\n* Patients with hypersensitivity or allergy to radiocolloid\n* Patients without complete documentation required for this study\n* Pregnant patients\n* Psychiatric patients\n* Male patients",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}